by Clinical Neuropsychologist Online | Wednesday, September 9, 2026 | Dementia
Abstract INTRODUCTION Blood plasma biomarkers identifying Alzheimer’s disease (AD) neuropathology offer accessible and scalable alternatives to lumbar puncture and positron emission tomography (PET) scans, with potential efficiency gains in clinical trial...
by Clinical Neuropsychologist Online | Wednesday, September 9, 2026 | Dementia
Dementia, Ahead of Print. If you do not see content above, kindly GO TO SOURCE. Not all publishers encode content in a way that enables republishing at Neuro.vip. This post is Copyright: | September 9, 2026 Neuro-Dementia Previous...
by Clinical Neuropsychologist Online | Wednesday, September 9, 2026 | Dementia
Abstract INTRODUCTION Adults with Down syndrome (DS) have a higher risk of Alzheimer’s disease (AD). As gut microbiota (GM) alterations have been reported in AD, we investigated their association with cognitive decline and plasma AD biomarkers in DS. METHODS...
by Clinical Neuropsychologist Online | Wednesday, September 9, 2026 | Dementia
Abstract INTRODUCTION Efficient cerebral microhemorrhage (MCH) monitoring is critical for anti-amyloid therapy safety due to amyloid-related imaging abnormalities with hemosiderin deposition (ARIA-H) risk. We developed MCH-Guard, a multimodal machine-learning...
by Clinical Neuropsychologist Online | Wednesday, September 9, 2026 | Dementia
Abstract INTRODUCTION Motoric cognitive risk syndrome (MCR) is a predementia condition that predicts multiple adverse health outcomes. Age-friendly environments (AFE) represent a key strategy for promoting healthy aging and may reduce MCR risk. However, little is...
